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Background: Patients with atrial fibrillation (AF) and high thrombotic risk should be protected from 
thromboembolic events with adequate oral anticoagulation therapy. In Croatia, direct oral anticoag-
ulant drugs (DOACs) are only partially reimbursed whereas optimal dosing of vitamin K antagonist 
(VKA) is hard to obtain.1 Aim: To investigate differences in characteristics and clinical outcomes of 
patients with AF exposed to different types of anticoagulant drugs. 
Patients and Methods: We retrospectively analyzed 1000 consecutive patients with non-valvular AF 
hospitalized in our institution in a period from 2013 to 2018. Patients were followed-up for a median 
time of 42 months. 
Results: DOAC penetration as initial anticoagulation therapy increased from 37% to 58% (P=0.002 for 
trend). Patients anticoagulated with VKA had more unfavorable thromboembolic and bleeding risk 
factors than DOAC patients, whereas risk factors were similarly distributed among three DOAC sub-
groups. Only 37% of patients using VKA had optimal dosing control, whereas three groups of DOAC pa-
tients had optimal dosing in >92% of cases. There were significantly more thromboembolic and bleed-
ing events among patients with poorly controlled VKA therapy in comparison to patients exposed to 
DOACs or optimal VKA (15% vs 3% thrombotic events, and 14% vs 4% bleeding events, respectively). 
After adjusting for all factors unbalanced at baseline and for optimal dosing, significant difference in 
thrombotic and bleeding events between VKA and DOACs was lost. However, patients who received 
VKA at baseline, irrespective of optimal dosing, had higher mortality even after adjusting for all factors 
unbalanced at baseline. Permanent discontinuation of therapy was very rare, whereas 18% of patients 
experienced therapy switch. Only 46% of patients with poorly controlled VKA therapy, and only 24% of 
patients who experienced a thrombotic event while actively taking VKA, experienced a therapy switch 
immediately after the event. 
Conclusion: Despite a steady trend of increased DOAC use in AF, higher risk patients still receive VKA 
relatively more often possibly due to socio-economic reasons. They also rarely obtain optimal dos-
ing control, rarely switch therapy after events, and have significantly shorter survival compared to 
patients on DOACs.
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